Teicoplanin: an alternative drug for the treatment of COVID-19?
Teicoplanin: an alternative drug for the treatment of COVID-19?
复制标题
DOI：
10.1016/j.ijantimicag.2020.105944
复制
发表时间：
2020-04-01
影响因子：
10.8
通讯作者：
Rolain, Jean-Marc
中科院分区：
文献类型：
--
作者：
Baron, Sophie Alexandra;Devaux, Christian;Rolain, Jean-Marc
2019年12月，一种新的冠状病毒，命名为严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)，从中国出现，引起肺炎暴发，首先在武汉中国地区，然后因其可能的高传播效率而在全球范围内传播。由于缺乏有效和具体的治疗方法以及控制疫情的需要，药物再利用似乎是找到治疗解决办法的最佳工具。氯喹、雷米地韦、洛比那韦、利巴韦林和利托那韦对冠状病毒有体外抑制作用。替考拉宁是一种用于治疗葡萄球菌感染的抗生素，此前在人类细胞中显示出抑制中东呼吸综合征冠状病毒(MERS-CoV)病毒生命周期第一阶段的效果。这种活性对SARS-CoV-2是保守的，因此将替考拉宁作为这种病毒患者的潜在治疗方法。(C)2020 Elsevier B.V.和国际化疗学会。版权所有。
In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.